This year’s meeting of the American Society of He­ma­tol­ogy (ASH) was held De­cem­ber 8 through 11 in Atlanta.

During the meeting, The Beacon pub­lished daily up­dates that provided overviews of the im­por­tant mul­ti­ple myeloma findings pre­sented during the meeting.  After the meeting concluded, The Beacon began pub­lishing in-depth articles about the key re­search findings.

This article, how­ever, shifts the focus to the bigger picture: What were the key findings of the meeting? Were there re­­sults with im­medi­ate implica­tions for the treat­ment of mul­ti­ple myeloma?  Did the re­search …

ARRY-520 is one of several potential new anti-myeloma agents that was highlighted at the American Society of Hematology (ASH) annual meeting earlier this week.

Initial results from two clinical trials show promise for ARRY-520 (filanesib), alone or in com­bi­na­tion with other myeloma drugs, as a thera­peutic option for heavily pretreated multiple myeloma patients.

“ARRY-520 shows promising activity in com­bi­na­tion with dexa­meth­a­sone in heavily pretreated myeloma patients,” said Dr. Jatin Shah, from the MD Anderson Cancer Center in Houston and lead investigator of both studies.

Based on their findings, the study investigators …

Monday was the third and next-to-last day of the 2012 American Society of Hematology (ASH) annual meeting.

It also was the busiest day of the meeting in regard to myeloma-related research.

The day ended with a poster session in the evening that featured over 1000 posters displayed throughout a large conference hall.  More than a hundred of the posters reported on the results of myeloma-related research.

Compared to the research summarized during oral presentations, the findings in poster summaries generally are in earlier stages of development.  They may involve laboratory research, clinical …

This year’s American Society of Hematology (ASH) meeting con­tinues in Atlanta.  Yesterday was the third day of the meeting and the busiest day in terms of myeloma-related presentations.  It was packed full of both oral and poster presentations.

There were so many myeloma-related talks given yesterday that many of them were held simultaneously.  The Beacon will therefore summarize presentations from the four most important sessions in updates such as this one.

This update covers presentations from the second of the four key oral presentation sessions.  An update published yesterday covers presentations from …

During the upcoming annual meeting of the American Society of Hematology (ASH), which will be held December 8 through 11 in Atlanta, results will be presented from clin­i­cal trials involving a number of poten­tial new drugs under devel­op­ment for the treat­ment of multiple myeloma.

In particular, results for newer, lesser known agents that are in the early stages of clin­i­cal devel­op­ment will take center stage. These agents in­clude ARRY-520 (filanesib), BHQ880, circularly permuted TRAIL, daratumumab, dinaciclib, lorvotuzumab mertansine, oprozomib, and tabalumab.

According to the recently …

Results from a number of multiple myeloma studies were presented yesterday during the second day of the American Society of Hematology (ASH) 2011 annual meeting in San Diego.

Predicting Response To Immunomodulatory Drugs

During an oral presentation and a poster presentation yesterday, researchers discussed the role of the protein cereblon in the treatment of myeloma.  Results from one study (abstract) in myeloma cell lines suggested that cereblon plays a key role in whether multiple myeloma patients respond to the immunomodulatory drugs Revlimid (lenalidomide) and pomalidomide.  Another study (abstract) …

Yesterday was the first day of the American Society of He­ma­tol­ogy (ASH) 2011 annual meeting, which is being held in San Diego.

Although the day featured no oral pre­sen­ta­tions of new myeloma-related re­search, it started with an in­ter­est­ing educational session focused on mul­ti­ple myeloma.

There also were a num­ber of poster pre­sen­ta­tions during the day summarizing im­por­tant new re­search findings.

The educational session in the morn­ing featured three pre­sen­ta­tions by lead­ing myeloma spe­cialists.

Induction Therapy And Maintenance Treatment

The first pre­sen­ta­tion was by Dr. Donna Reece of the Princess Margaret Hospital in …